Steele Lab

Substance use disorders (SUDs), a chronic relapsing biological brain disease, affect too many people worldwide. Current treatments for SUDs are sadly insufficient to tackle this huge issue. New treatments, based on our understanding of the chronic relapsing biological nature of the disease, must be developed. The lab is positioned to bridge the translational gap between neuroimaging research and treatment of SUDs. The first step is to identify malleable circuits that could be targeted with chronic interventions. The lab uses transcranial magnetic stimulation (TMS) to modulate circuits and measures the malleability of targeted circuits with functional magnetic resonance imaging (fMRI), electroencephalography (EEG), and event-related potentials (ERPs). We seek to work closely with treatment providers to rapidly develop and implement viable treatments for individuals with SUDs.